People on insulin therapy are challenged with evaluation of numerous factors affecting the blood glucose in order to select the optimal dose for reaching their glucose target. Following medical recommendations precisely still results in considerable blood glucose unpredictability, often resulting in frustration in the short term due to hypoglycemia and hyperglycemia, and, in the long term, will likely result in complications.
The kinetics of insulin do indeed vary significantly and have become an important focus when developing new insulin analogues and delivery systems; however, numerous of other factors impact glycemic variability. These have different dependences and interactions and are therefore difficult to characterize. Some of the factors are highly dependent and influenced by the type of insulin and devices used in therapy. Development of future therapy products is therefore highly focused on how to minimize glycemic variability.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet.1998;352 (9131): 837–53.
2.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med.1993;329 (14): 977–86.
3.
KleinOLyngeJEndahlLDamholtBNosekLHeiseT. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab.2007;9 (3): 290–9.
4.
HeinemannLWeyerCRauhausMHeinrichsSHeiseT. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care.1998;21 (11): 1910–4.
5.
HeiseTNosekLRønnBBEndahlLHeinemannLKapitzaCDraegerE. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes.2004;53 (6): 1614–20.
6.
GallowayJASpradlinCTNelsonRLWentworthSMDavidsonJASwarnerJL. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care.1981;4 (3): 366–76.
7.
ChenJWChristiansenJSLauritzenT. Limitations to subcutaneous insulin administration in type 1 diabetes. Diabetes Obes Metab.2003;5 (4): 223–33.
8.
KeithKNicholsonDRogersD. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila).2004;43 (1): 69–74.
9.
LteifANSchwenkWF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care.1999;22 (1): 137–40.
10.
AsakuraTSeinoHKageyamaMYohkohN. Dosing accuracy of two insulin pre-filled pens. Curr Med Res Opin.2008;24 (5): 1429–34.
11.
BodeBWTamborlaneWVDavidsonPC. Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes. Postgrad Med.2002;111 (5): 69–77.
12.
HeinemannL. Variability of insulin absorption and insulin action. Diabetes Technol Ther.2002;4 (5): 673–82.
13.
StewartNLDarlowBA. Insulin loss at the injection site in children with type 1 diabetes mellitus. Diabet Med.1994;11 (8): 802–5.
14.
VaagAHandbergALauritzenMHenriksenJEPedersenKDBeck-NielsenH. Variation in absorption of NPH insulin due to intramuscular injection. Diabetes Care.1990;13 (1): 74–6.
15.
SwanKLDziuraJDSteilGMVoskanyanGRSikesKASteffenATMartinMLTamborlaneWVWeinzimerSA. Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care.2009;32 (2): 240–4.
16.
BergmanRNFinegoodDTAderM. Assessment of insulin sensitivity in vivo. Endocr Rev.1985;6 (1): 45–86.
17.
HeinemannL. Variability of insulin absorption and insulin action. Diabetes Technol Ther.2002;4 (5): 673–82.
18.
SteilGMMurrayJBergmanRNBuchananTA. Repeatability of insulin sensitivity and glucose effectiveness from the minimal model. Implications for study design. Diabetes.1994;43 (11): 1365–71.
19.
SpyerGHattersleyATMacDonaldIAAmielSMacLeodKM. Hypoglycaemic counter-regulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes. Lancet.2000;356 (9246): 1970–4.
20.
CryerPE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia.2002;45 (7): 937–48.
21.
KarpeFFieldingBAIlicVMacDonaldIASummersLKFraynKN. Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes.2002;51 (8): 2467–73.
22.
AltoWAMeyerDSchneidJBrysonPKindigJ. Assuring the accuracy of home glucose monitoring. J Am Board Fam Pract.2002;15 (1): 1–6.
23.
GuelfiKJJonesTWFournierPA. The decline in blood glucose levels is less with intermittent high-intensity compared with moderate exercise in individuals with type 1 diabetes. Diabetes Care.2005;28 (6): 1289–94.
24.
BolliGBGerichJE. The “dawn phenomenon”—a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med.1984;310 (12): 746–50.
25.
ValdesCTElkind-HirschKE. Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle. J Clin Endocrinol Metab.1991;72 (3): 642–6.
26.
Van CauterEPolonskyKSScheenAJ. Roles of circadian rhythmicity and sleep in human glucose regulation. Endocr Rev.1997;18 (5): 716–38.
27.
KildegaardJRandløvJPoulsenJUHejlesenOK. Non-model related variations profoundly impact blood glucose prediction. Proceedings of the Sixth Annual Diabetes Technology Meeting. Atlanta, GA. November 2–4, 2006.
28.
GraffMRGrossTMJuthSECharlsonJ. How well are individuals on intensive insulin therapy counting carbohydrates?Diabetes Res Clin Pract.2000Suppl 1; 50: 238–9.
29.
MohammedNHWoleverTM. Effect of carbohydrate source on post-prandial blood glucose in subjects with type 1 diabetes treated with insulin lispro. Diabetes Res Clin Pract.2004;65 (1): 29–35.
30.
BurdickJChaseHPSloverRHKnievelKScrimgeourLManiatisAKKlingensmithGJ. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics.2004;113 (3 Pt 1): e221–4.
31.
OlinderALKernellASmideB. Missed bolus doses: devastating for metabolic control in CSII-treated adolescents with type 1 diabetes. Pediatr Diabetes.2009;10 (2): 142–8.
32.
AlemazadeRGoldbergTFortPReckerBLifshitzF. Reported dietary intakes of patients with insulin-dependent diabetes mellitus: limitations of dietary recall. Nutrition.1992;8 (2): 87–93.
33.
KalergisMNadeauJPacaudDYaredZYaleJF. Accuracy and reliability of reporting self-monitoring of blood glucose results in adults with type 1 and type 2 diabetes. Canadian J Diabetes.2006;30 (3): 241–47.
34.
SchüttMKernWKrauseUBuschPDappAGrziwotzRMayerIRosenbauerJWagnerCZimmermannAKernerWHollRW, DPV Initiative. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria. Exp Clin Endocrinol Diabetes.2006;114 (7): 384–8.
SkeieSThueGNerhusKSandbergS. Instruments for self-monitoring of blood glucose: comparisons of testing quality achieved by patients and a technician. Clin Chem.2002;48 (7): 994–1003.
37.
KovachevBAndersonSHeinemannLClarkeW. Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Diabetes Care.2008;31 (6): 1160–4.
38.
International Organization for Standardization. In vitro diagnostic test systems: requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus (ISO 15197). Geneva: International Organization for Standardization; 2003.
39.
BodeBSilverMWeissRMartinK. Evaluation of a continuous glucose monitoring system for home-use conditions. Manag Care.2008;17 (8): 40–5.
40.
BuckinghamBCobryEClintonPGageVCaswellKKunselmanECameronFChaseHP. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Technol Ther.2009;11 (2): 93–7.
41.
GrossTMKayneDKingARotherCJuthS. A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy. Diabetes Technol Ther.2003;5 (3): 365–9.
